Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15677593 | 0.85 | CHRNB2 (0.46) | CHRNB2CHRNA4CYP1A2CYP2D6CHRNA7 | |
| SCHEMBL26806573 | 0.85 | CYP1A2 (0.47) | CHRNB2CHRNA4CYP1A2CYP2D6CHRNA7 | |
| SCHEMBL21844332 | 0.84 | CHRNB2 (0.46) | CHRNB2CHRNA4CYP1A2CYP2D6CHRNA7 | |
| SCHEMBL10202878 | 0.82 | CHRNB2 (0.43) | CHRNB2CHRNA4CYP1A2CYP2D6CHRNA7 | |
| SCHEMBL28795779 | 0.82 | EPHX2 (0.57) | CYP1A2CYP2A6 | |
| SCHEMBL17102177 | 0.80 | SLC16A3 (0.57) | CYP1A2TDP1NAPRT | |
| SCHEMBL14498994 | 0.79 | L3MBTL1 (0.57) | CYP1A2CYP2D6CHRNA7L3MBTL1TDP1 | |
| SCHEMBL10263684 | 0.79 | CHRNB2 (0.45) | CHRNB2CHRNA4CYP1A2CYP2D6CHRNA7 | |
| SCHEMBL10202643 | 0.78 | CHRM2 (0.48) | CHRNB2CHRNA4CYP1A2CYP2D6CHRNA7 | |
| SCHEMBL445750 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238324-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238324-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2024-07-18 | — | — | US | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11707480-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| US-7928135-B2 | Benzene, pyridine, and pyridazine derivatives | SERENEX, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7906529-B2 | Benzene, pyridine, and pyridazine derivatives | SERENEX, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110034529-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090023734-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7358370-B2 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | SERENEX, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7282608-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2007-10-16 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-20070105781-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | CHRNB2 583/4885CHRNA4 482/4885CYP1A2 667/4885 |
| US-20090023734-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC6 | CHRNB2 4595/4885CHRNA4 4660/4885CYP1A2 4444/4885 |
| US-11707480-B2 | Highly active compounds against COVID-19 | PNP, MTAP, ACE2 | CHRNB2 4551/4885CHRNA4 4338/4885CYP1A2 4042/4885 |
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | CHRNB2 4855/4885CHRNA4 4716/4885CYP1A2 1290/4885 |
| US-20070105781-A1 | Inhibitors of serine proteases | PRSS1, SERPINB1, PRSS3 | CHRNB2 4837/4885CHRNA4 4883/4885CYP1A2 2269/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | CHRNB2 4685/4885CHRNA4 4728/4885CYP1A2 1898/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | CHRNB2 4685/4885CHRNA4 4728/4885CYP1A2 1898/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | CHRNB2 4568/4885CHRNA4 4673/4885CYP1A2 1599/4885 |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | CHRNB2 4855/4885CHRNA4 4716/4885CYP1A2 1290/4885 |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | GPR17, GPR18, GPR119 | CHRNB2 368/4885CHRNA4 238/4885CYP1A2 1013/4885 |
| US-20110034529-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | CHRNB2 2384/4885CHRNA4 858/4885CYP1A2 140/4885 |
| US-20240238324-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | PNP, MTAP, ACE2 | CHRNB2 4551/4885CHRNA4 4338/4885CYP1A2 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.